What is HC Wainwright’s Estimate for ACRV FY2029 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – HC Wainwright issued their FY2029 earnings per share estimates for Acrivon Therapeutics in a research report issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($1.25) for the year. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

Other analysts have also recently issued research reports about the company. KeyCorp began coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They set an “overweight” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Acrivon Therapeutics in a research note on Wednesday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $23.17.

Acrivon Therapeutics Stock Down 11.1 %

Shares of NASDAQ:ACRV opened at $2.24 on Thursday. The firm has a fifty day moving average of $5.35 and a two-hundred day moving average of $6.53. Acrivon Therapeutics has a 12-month low of $2.14 and a 12-month high of $11.90. The firm has a market capitalization of $69.74 million, a P/E ratio of -0.83 and a beta of 0.85.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.06.

Hedge Funds Weigh In On Acrivon Therapeutics

Several large investors have recently made changes to their positions in ACRV. Barclays PLC raised its stake in Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after purchasing an additional 11,273 shares during the last quarter. State Street Corp grew its position in Acrivon Therapeutics by 26.4% during the third quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after buying an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after acquiring an additional 28,748 shares during the period. Exome Asset Management LLC acquired a new position in Acrivon Therapeutics in the 3rd quarter valued at approximately $817,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Acrivon Therapeutics in the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.